NCT06313996 2026-03-18
A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 3 Withdrawn
Clinical Trials
208 trialsNCT07313891 2026-03-17
BOOST
Relmada Therapeutics, Inc.
Phase 3 Withdrawn
NCT07342517 2026-03-17
RESCUE
Relmada Therapeutics, Inc.
Phase 3 Withdrawn
NCT06585969 2026-02-12
DISCORDANT
Danish Breast Cancer Cooperative Group
Phase 3 Withdrawn
NCT07092475 2025-11-26
The Impact of Intraoperative Methadone on Postoperative Opioid Use
University of Utah
Phase 3 Withdrawn
NCT06884254 2025-10-14
EGC102
EirGenix, Inc.
Phase 3 Withdrawn
NCT06254742 2025-08-07
A Trial of HHPG-19K Injection and Auto-HHPG-19K Injection in Prevention of Chemotherapy-related Moderate to Severe Neutropenia of Patients With Nonmyeloid Malignancies
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Withdrawn
NCT02446652 2025-05-29
Evaluation of TRANSKRIP ® Plus Chemotherapy in Recurrent-Persistent Cervical Cancer
National Institute of Cancerología
Phase 3 Withdrawn
NCT06795178 2025-04-27
KATANA E3M
Foresee Pharmaceuticals Co., Ltd.
Phase 3 Withdrawn
NCT06795191 2025-04-27
KATANA E6M
Foresee Pharmaceuticals Co., Ltd.
Phase 3 Withdrawn
NCT01345084 2025-03-28
NICAP
Eurofarma Laboratorios S.A.
Phase 3 Withdrawn
NCT00733122 2025-03-03
Tolerability and Immunogenicity of Gardasil in Females Between 16 and 23 Years of Age in India (V501-034)
Merck Sharp & Dohme LLC
Phase 3 Withdrawn
NCT03632798 2025-02-12
ACSCO
Cordgenics, LLC
Phase 3 Withdrawn
NCT04488159 2024-09-20
iMAGINE
Medical University of Vienna
Phase 3 Withdrawn
NCT03747562 2024-09-19
stREnGTH
University Hospital, Ghent
Phase 3 Withdrawn
NCT06370871 2024-07-17
Brightline-3: A Study to Find Out Whether Brigimadlin in Combination With Ezabenlimab Helps People With Advanced Soft Tissue Sarcoma
Boehringer Ingelheim
Phase 3 Withdrawn
NCT06093503 2024-06-26
Study of Intravenous Telisotuzumab Vedotin in Combination Osimertinib or Standard of Care Chemotherapy to Assess Change in Disease Activity in Adult Participants With Non-Small Cell Lung Cancer That Has a Mutation in the Epidermal Growth Factor Receptor Gene and That Overexpresses the c-Met Protein
AbbVie
Phase 3 Withdrawn
NCT06232707 2024-05-31
ALUMMINATE
Celgene
Phase 3 Withdrawn
NCT05403580 2024-05-06
Olanzapine for the Treatment of Chronic Nausea and/or Vomiting in Patients With Advanced Cancer
Mayo Clinic
Phase 3 Withdrawn
NCT05707702 2024-05-01
Lactobacillus Lozenges as Preventative Care in Low-grade Dysplasia
Boston Medical Center
Phase 3 Withdrawn
NCT06301308 2024-04-24
A Novel Application of 2% Lidocaine Injection for Male Rigid cycstoscopy-a Patient-blinded Randomised Trial
Second Xiangya Hospital of Central South University
Phase 3 Withdrawn
NCT06205290 2024-04-02
A Study to Compare the Efficacy and Safety of Lisocabtagene Maraleucel vs Investigator's Choice Options in Adult Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, Whose Disease Has Failed Treatment With Both BTKi and BCL2i Therapies
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 3 Withdrawn
NCT05474690 2024-02-26
A Study Comparing the Efficacy of TCbHP and ECHP-THP in the Neoadjuvant Treatment of HER2-positive Breast Cancer
Henan Cancer Hospital
Phase 3 Withdrawn
NCT04029857 2024-02-13
Nutritional Supplementation in Reducing Complications in Patients With Locally Advanced Esophageal Cancer Undergoing Chemotherapy, Radiation Therapy, and/or Surgery
M.D. Anderson Cancer Center
Phase 3 Withdrawn
NCT04760288 2024-01-05
AcceleRET-MTC
Hoffmann-La Roche
Phase 3 Withdrawn
NCT02519140 2023-12-04
Assessing How the Viscosity of Submucosal Gel Injections Helps With Endoscopic Mucosal Resections
Maimonides Medical Center
Phase 3 Withdrawn
NCT05712941 2023-11-03
Comparison of Letrozole With Lerociclib Versus Letrozole With Placebo Control in Patients With Advanced/Metastatic or Recurrent, Grade 1 or Grade 2 Endometrial Cancer
EQRx International, Inc.
Phase 3 Withdrawn
NCT05261646 2023-09-28
A Clinical Study of Hetrombopag Olamine Tablets in Adults Receiving 21-day Cycles of Chemotherapy for Solid Tumours, Who Are Delayed for at Least 1 Week From Their Scheduled Cycle Because of Chemotherapy-induced Thrombocytopenia
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Withdrawn
NCT05771896 2023-09-14
CARE
GenesisCare USA
Phase 3 Withdrawn
NCT05098327 2023-08-15
Pioglitazone and Insulin Resistance in ADT
State University of New York at Buffalo
Phase 3 Withdrawn
NCT00488605 2023-08-03
H-9926-LCH III: Treatment Protocol of the Third International Study for Langerhans Cell Histiocytosis
University of New Mexico
Phase 3 Withdrawn
NCT05791097 2023-07-24
AdvanTIG-306
Novartis
Phase 3 Withdrawn
NCT04466917 2023-07-03
A Study of ABP 215 Versus Bevacizumab in Chinese Subjects With Advanced Non-Squamous Non-Small Cell Lung Cancer
Amgen
Phase 3 Withdrawn
NCT05363644 2023-06-29
BioDFence® G3 For Full Nerve-Sparing Robotic-Assisted Radical Prostatectomy
AdventHealth
Phase 3 Withdrawn
NCT05564338 2023-06-07
Efficacy and Safety of Sitravatinib Plus Tislelizumab or Placebo Plus Tislelizumab Versus Placebo as Adjuvant Treatment in Participants With Hepatocellular Carcinoma
BeiGene
Phase 3 Withdrawn
NCT05431179 2023-04-21
A Study of Zilovertamab and Ibrutinib in Patients With Relapsed or Refractory Mantle Cell Lymphoma
Oncternal Therapeutics, Inc
Phase 3 Withdrawn
NCT05325164 2022-12-05
METHADOPT
Ottawa Hospital Research Institute
Phase 3 Withdrawn
NCT04943627 2022-10-05
Balstilimab Versus Investigator Choice Chemotherapy in Patients With Recurrent Cervical Cancer (BRAVA)
Agenus Inc.
Phase 3 Withdrawn
NCT02201381 2022-07-18
METRICS
Health Clinics Limited
Phase 3 Withdrawn
NCT04796922 2022-07-18
To Evaluate Efficacy and Safety of Parsaclisib Plus Either Rituximab or Obinutuzumab in R/R Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL) (CITADEL-302)
Incyte Corporation
Phase 3 Withdrawn
NCT04676243 2022-05-25
Q-SOC
University Hospital Heidelberg
Phase 3 Withdrawn
NCT04465734 2022-05-05
A Clinical Study to Compare the Efficacy and Safety of HLX10 in Combination With HLX04 Versus Sorafenib as the First-line Treatment in Patients With Locally Advanced or Metastatic HCC
Shanghai Henlius Biotech
Phase 3 Withdrawn
NCT04806945 2022-05-05
A Phase III Study to Evaluate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy in Patients With Advanced Cervical Cancer
Shanghai Henlius Biotech
Phase 3 Withdrawn
NCT04849715 2022-04-29
CITADEL-310
Incyte Corporation
Phase 3 Withdrawn
NCT00255138 2022-04-01
Efficacy of Atomoxetine Therapy Versus Placebo for Cognitive Late Effects
Temple University
Phase 3 Withdrawn
NCT03905902 2021-12-23
VITALIA
Sotio Biotech Inc.
Phase 3 Withdrawn
NCT04859582 2021-12-16
KEYNOTE-859
Merck Sharp & Dohme LLC
Phase 3 Withdrawn
NCT02848716 2021-11-17
LiLACs
Institut Claudius Regaud
Phase 3 Withdrawn
NCT04572776 2021-11-09
Phase 3 Study to Assess Resiniferatoxin vs Standard of Care for the Treatment of Intractable Cancer Pain
Sorrento Therapeutics, Inc.
Phase 3 Withdrawn
NCT03806049 2021-07-15
Trial Comparing Niraparib-bevacizumab-Dostarlimab and Niraparib-bevacizumab to Standard of Care in Recurrent Ovarian Cancer
Nordic Society of Gynaecological Oncology - Clinical Trials Unit
Phase 3 Withdrawn